Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 2/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.43 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 12/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 11/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 4/20 | 0.37 |
| ▸ | FEN1 | P39748 | 4/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1398794 | 1.00 | HCRTR1 (0.43) | HCRTR1HCRTR2UCHL1USP30OPRK1 | |
| SCHEMBL29010641 | 0.81 | OPRK1 (0.49) | HCRTR1HCRTR2UCHL1USP30OPRK1 | |
| SCHEMBL1398793 | 0.75 | FEN1 (0.50) | HCRTR1HCRTR2UCHL1USP30OPRK1 | |
| SCHEMBL31717173 | 0.75 | MMP2 (0.51) | HCRTR1HCRTR2OPRK1OPRM1 | |
| SCHEMBL1398849 | 0.74 | ALOX5AP (0.58) | HCRTR1HCRTR2UCHL1USP30OPRK1 | |
| SCHEMBL28969716 | 0.74 | ALOX15 (0.54) | OPRK1OPRM1 | |
| SCHEMBL28546624 | 0.72 | TSHR (0.55) | HCRTR1HCRTR2OPRK1OPRM1KCNH2 | |
| SCHEMBL31716763 | 0.70 | CASP3 (0.50) | HCRTR1HCRTR2OPRK1OPRM1ALOX5AP | |
| SCHEMBL1398741 | 0.70 | CKS1B (0.48) | OPRK1OPRM1 | |
| SCHEMBL31716758 | 0.69 | GHSR (0.55) | OPRK1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994336-B2 | Azetidine compounds as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-08-09 | — | — | US | disclosed |
| EP-2069332-B1 | AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-03-02 | — | — | EP | disclosed |
| US-20100222600-A1 | AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222600-A1 | AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | HCRTR1 2/4885HCRTR2 1/4885UCHL1 2010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.